About

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium is seeking a potential strategic partner for in the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

Robust Pipeline

Actinium Pharmaceuticals' drug development pipeline features Iomab-B with positive pivotal Phase 3 results, Iomab-ACT, which is intended to be a conditioning regimen for cell and gene therapies and Actimab-A, which is being studied in combination with other regimens in AML to leverage its mutation-agnostic, resistant mechanism of action in collaboration under the NCI CRADA for late-stage development. Actinium is focused on continuing to expand its drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors.

View Pipeline

About

Robust Pipeline

Email Sign Up